18 47

Cited 0 times in

What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?

Authors
 Ji-Guang Wang  ;  Yook-Chin Chia  ;  Chen-Huan Chen  ;  Sungha Park  ;  Satoshi Hoshide  ;  Naoko Tomitani  ;  Tomoyuki Kabutoya  ;  Jinho Shin  ;  Yuda Turana  ;  Arieska Ann Soenarta  ;  Jam Chin Tay  ;  Peera Buranakitjaroen  ;  Jennifer Nailes  ;  Huynh Van Minh  ;  Saulat Siddique  ;  Jorge Sison  ;  Guru Prasad Sogunuru  ;  Apichard Sukonthasarn  ;  Boon Wee Teo  ;  Narsingh Verma  ;  Yu-Qing Zhang  ;  Tzung-Dau Wang  ;  Kazuomi Kario 
Citation
 JOURNAL OF CLINICAL HYPERTENSION, Vol.22(3) : 363-368, 2020-03 
Journal Title
JOURNAL OF CLINICAL HYPERTENSION
ISSN
 1524-6175 
Issue Date
2020-03
MeSH
Aged ; Antihypertensive Agents / pharmacology* ; Antihypertensive Agents / therapeutic use ; Asia / epidemiology ; Blood Pressure / drug effects ; China / epidemiology ; Humans ; Hypertension* / diagnosis ; Hypertension* / drug therapy ; Hypertension* / epidemiology
Keywords
China ; guideline ; hypertension ; management
Abstract
The new Chinese hypertension guideline comprehensively covers almost all major aspects in the management of hypertension. In this new guideline, hypertension remains defined as a systolic/diastolic blood pressure of at least 140/90 mm Hg. For risk assessment, a qualitative approach is used similarly as in previous Chinese guidelines according to the blood pressure level and the presence or absence of other risk factors, target organ damage, cardiovascular complications, and comorbid diseases. The therapeutic target is 140/90 mm Hg in general, and if tolerated, especially in high-risk patients, can be more stringent, that is, 130/80 mm Hg. However, a less stringent target, that is, 150/90 mm Hg, is used in the younger (65-79 years, if tolerated, 140/90 mm Hg) and older elderly (>= 80 years). Five classes of antihypertensive drugs, including beta-blockers, can be used either in initial monotherapy or combination. The guideline also provided information on the management of hypertension in several special groups of patients and in the presence of secondary causes of hypertension. To implement the guideline recommendations, several nationwide hypertension control initiatives are being undertaken with new technology. The new technological platforms hopefully will help improve the management of hypertension and generate scientific evidence for future hypertension guidelines, including a possible Asian hypertension guideline in the near future.
Files in This Item:
T9992020392.pdf Download
DOI
10.1111/jch.13803
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Sung Ha(박성하) ORCID logo https://orcid.org/0000-0001-5362-478X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190167
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links